Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioxel prepares to market generic Taxotere
The patents on the drug are due to expire at the end of 2007, which will allow the biopharmaceutical company to develop generic Taxotere, which generated worldwide sales
The patents on the drug are due to expire at the end of 2007, which will allow the biopharmaceutical company to develop generic Taxotere, which generated worldwide sales
In what is described as the largest diabetes-prevention trial ever conducted, Avandia (rosiglitazone) reduced the risk of developing type 2 diabetes by 62% relative to placebo among people
The companies are collaborating to develop and commercialize Schering's novel selective estrogen receptor downregulator (SERD,) for the treatment of breast cancer. AstraZeneca – which is looking to rebuild
Dr Agop Bedikian, the lead author on the paper, said: “This was the first trial to achieve such a broad array of positive endpoints. I believe the aggregate
Single doses of Hematide resulted in dose-dependent increases in circulating reticulocytes in normal healthy volunteers and in a clinically and statistically significant increase in red blood cells and
The company said that it plans to assess whether there is an opportunity to continue development of CTI-01 with a collaborative partner or to out-license the drug. Critical
A research group headed by James Morre, professor of medicinal chemistry at Purdue University, obtained results supporting that Phenoxodiol specifically targets a protein on prostate cancer cells known
SCV-07 works by stimulating the immune system through its effects on T-helper 1 cells, which are essential for clearance of viral infections. The trial found the treatment to
The trial of MethylGene’s lead histone deacetylase (HDAC) inhibitor product candidate, MGCD0103, will use specific patient populations including patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma,
Campath is approved to treat B-cell chronic lymphocytic leukemia. The company had to halt its study using the drug for treating MS in September 2005, after three patients